We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Tick-Borne Disease Threatens Primarily Immune Suppressed Persons

By LabMedica International staff writers
Posted on 16 Jun 2014
A newly discovered tick-borne bacterium known as Candidatus Neoehrlichia mikurensis has been implicated in six cases of the disease in Sweden.

The bacterium, which is spread by rodents and ticks mainly in Asia and Europe, including Sweden, has been found in 19 cases worldwide and is primarily a risk for people who are already sick and who are receiving immunosuppressive drugs.

Scientists at the University of Gothenburg (Sweden) working with their European colleagues compiled clinical and laboratory data from 11 patients with hematological malignances or autoimmune diseases who were diagnosed with Ca. N. More...
mikurensis infection in Europe from 2010 to 2013. The patients had a median age of 67, were mostly male (8/11), and resided in Sweden, Switzerland, Germany, and the Czech Republic. All but one had ongoing or recent immune suppressive treatment and a majority were splenectomized (8/11).

The most abnormal laboratory findings among all the patients was elevation of the acute phase reactant C-reactive protein in serum, with levels ranging from 4- to 74-fold higher than the cutoff level. Leukocytosis with neutrophilia and anemia were also typical findings. About half of the patients had at some point raised levels of lactate dehydrogenase in serum and hyponatremia, respectively. Lowered platelet counts and elevated transaminase concentrations were rare findings.

The diagnosis of Ca. Neoehrlichia infection was in all cases based on pan-bacterial polymerase chain reaction (PCR) analysis of segments of the 16S ribosomal ribonucleic acid (rRNA) gene followed by sequence and homology analyses. Once neoehrlichiosis has been diagnosed, the patients recover completely after treatment with antibiotics. Physicians within the fields of rheumatology, hematology, oncology, and infectious diseases should be aware of this new infectious agent and their attention drawn to patients with suspected recurrence of the underlying autoimmune or hematologic disease where the clinical picture is atypical.

Christine Wennerås, MD, PhD, the senior author of the study said, “The bacterium cannot be grown in culture, and this means that it is not picked up in routine diagnostic procedures. Furthermore, the symptoms are deceptive. Several patients, for example, have been affected by blood clots in the leg or the blood vessels in the head, and this has not been coupled to an infectious cause. Other typical symptom such as fever, muscle pain and joint pain can be caused also by the patient’s underlying disease. We know very little about how the infection affects otherwise healthy people who are not taking immunosuppressive drugs.” The study was published online on March 18, 2014, in the journal Clinical Infectious Diseases.

Related Links:

University of Gothenburg



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Sample Transportation System
Tempus1800 Necto
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.